Fluanxol Depot: Uses, Dosage & Side Effects
Long-acting injectable antipsychotic for schizophrenia and psychosis
Quick Facts About Fluanxol Depot
Key Takeaways About Fluanxol Depot
- Long-acting depot injection: Fluanxol Depot is given as an intramuscular injection every 2–4 weeks, eliminating the need for daily oral medication and improving treatment consistency
- Treats schizophrenia and psychosis: It is indicated for the maintenance treatment of schizophrenia and other psychotic disorders, reducing positive symptoms such as hallucinations and delusions
- Do not stop abruptly: Sudden discontinuation can cause withdrawal symptoms including nausea, insomnia, anxiety, and muscle pain — always taper gradually under medical supervision
- Monitor for movement disorders: Extrapyramidal symptoms (tremor, stiffness, restlessness) and tardive dyskinesia are important side effects that require regular assessment
- Not suitable for everyone: Fluanxol Depot is not recommended in children, elderly patients with dementia, or those in states of reduced consciousness, including alcohol or opioid intoxication
What Is Fluanxol Depot and What Is It Used For?
Fluanxol Depot is a long-acting injectable antipsychotic containing flupentixol decanoate. It belongs to the thioxanthene class of antipsychotics and is used for the treatment of schizophrenia and other psychotic disorders. The depot formulation is injected into the gluteal muscle every 2 to 4 weeks, providing sustained and stable drug release between doses.
Flupentixol is a first-generation (typical) antipsychotic that has been used in clinical practice for over five decades. It acts primarily by blocking dopamine D1 and D2 receptors in the brain, particularly in the mesolimbic and mesocortical pathways. This dopamine receptor antagonism is the primary mechanism by which flupentixol reduces the positive symptoms of psychosis, including hallucinations (hearing or seeing things that are not real), delusions (fixed false beliefs), and disorganised thinking.
The depot formulation represents a significant clinical advantage over daily oral medication. In Fluanxol Depot, flupentixol is esterified with decanoic acid to form flupentixol decanoate, which is dissolved in a medium-chain triglyceride oil vehicle. When injected intramuscularly into the gluteal muscle, the oil solution creates a depot (reservoir) at the injection site. The ester bond is slowly hydrolysed by tissue esterases, gradually releasing free flupentixol into the bloodstream over a period of weeks. This pharmacokinetic profile ensures relatively constant plasma drug levels between injections, avoiding the peaks and troughs associated with oral dosing.
Long-acting injectable (LAI) antipsychotics such as Fluanxol Depot are particularly valuable in the treatment of schizophrenia because non-adherence to oral medication is extremely common in this patient population. Research published in the Journal of Clinical Psychiatry has demonstrated that mirror-image studies — comparing periods of oral versus LAI antipsychotic use in the same patients — consistently show that LAI formulations significantly reduce hospitalisation rates and relapse risk. The NICE guidelines for psychosis and schizophrenia recommend considering LAI antipsychotics for patients who prefer this route of administration or who have a history of non-adherence to oral therapy.
Schizophrenia
Schizophrenia is a chronic and often debilitating psychiatric disorder affecting approximately 1% of the global population. It is characterised by episodes of psychosis involving hallucinations, delusions, disorganised speech and behaviour, as well as negative symptoms such as social withdrawal, reduced emotional expression, and decreased motivation. Fluanxol Depot is used as maintenance treatment to prevent relapse and manage ongoing symptoms. The medication does not cure schizophrenia but can significantly improve quality of life by keeping symptoms under control when taken consistently.
Other psychotic disorders
Beyond schizophrenia, Fluanxol Depot may be prescribed for other psychotic conditions where long-term antipsychotic treatment is required. These include schizoaffective disorder and chronic delusional disorders. The decision to use a depot formulation is typically made by a psychiatrist after careful assessment of the patient's clinical history, previous response to oral antipsychotics, and treatment preferences.
Fluanxol Depot must be administered by a healthcare professional (doctor or nurse) as an intramuscular injection. It cannot be self-administered. The medication should only be used under the supervision of a psychiatrist or other specialist experienced in treating psychotic disorders. Your doctor will determine the appropriate dose and injection interval based on your individual response.
What Should You Know Before Receiving Fluanxol Depot?
Before starting Fluanxol Depot, inform your doctor about all existing medical conditions, current medications, and whether you are pregnant or breastfeeding. There are several important contraindications and warnings, including cardiovascular disease, liver impairment, seizure history, and phaeochromocytoma. The medication is not suitable for children or for elderly patients with dementia.
Fluanxol Depot is a potent medication with effects on multiple organ systems. Before the first injection, your doctor will conduct a thorough medical assessment to ensure the medication is safe and appropriate for you. This typically includes a physical examination, baseline blood tests (including liver function, blood glucose, and lipid profile), an electrocardiogram (ECG) to check your heart rhythm, and assessment of any movement disorders.
Contraindications
Fluanxol Depot must not be used in the following situations:
- Known allergy to flupentixol, flupentixol decanoate, or any of the excipients (including medium-chain triglycerides)
- Circulatory collapse — severe disturbances in blood circulation
- Reduced level of consciousness — such as poisoning with alcohol, sleeping pills, or strong opioid analgesics (morphine or similar)
- Comatose state — the medication should never be given to an unconscious patient
- Haematological dyscrasias — certain forms of blood disorders
- Phaeochromocytoma — a rare benign tumour of the adrenal glands that causes excessive production of catecholamines
Warnings and precautions
Tell your doctor before receiving Fluanxol Depot if you have any of the following conditions or risk factors:
- Liver impairment — flupentixol is metabolised by the liver, and dose adjustments may be required; additional blood tests may be needed
- History of seizures or epilepsy — antipsychotics can lower the seizure threshold
- Organic brain syndrome — brain damage caused by alcohol or solvent poisoning
- Stroke risk factors — including smoking, high blood pressure, diabetes, or dementia
- Cardiovascular disease — including heart failure, recent myocardial infarction, or family history of QT prolongation (an abnormality visible on ECG)
- Use of other antipsychotics — combining antipsychotics increases the risk of side effects
- Manic or hypomanic states — Fluanxol Depot may intensify these feelings
- Personal or family history of blood clots — antipsychotic medicines have been associated with venous thromboembolism (VTE)
- Low white blood cell count — Fluanxol Depot may rarely affect immune function
- Cancer treatment — inform your doctor if you are receiving chemotherapy or radiotherapy
- Elderly patients — increased sensitivity to side effects, particularly cardiovascular and neurological effects
Contact your doctor or emergency services immediately if you develop high fever combined with muscle rigidity, altered consciousness, excessive sweating, and rapid heartbeat. These may be signs of neuroleptic malignant syndrome, a rare but potentially life-threatening condition that can occur with any antipsychotic medication and requires immediate medical treatment.
A small increase in the number of deaths has been reported in elderly patients with dementia treated with antipsychotic medicines compared with those not receiving such treatment. Fluanxol Depot is not recommended for use in elderly patients with dementia-related psychosis. If you are caring for an elderly person with dementia, discuss safer alternatives with their doctor.
Dry mouth is a common side effect that, during long-term treatment, can increase the risk of dental and oral mucosal damage. Thorough tooth brushing with fluoride toothpaste twice daily is recommended throughout treatment.
Children and adolescents
Fluanxol Depot is not recommended for use in children and adolescents. The safety and efficacy of flupentixol decanoate have not been established in this population. If antipsychotic treatment is required for a young person, the prescribing doctor will consider age-appropriate alternatives with a better-established evidence base in paediatric populations.
Pregnancy and breastfeeding
If you are pregnant, think you may be pregnant, or are planning to become pregnant, discuss this with your doctor before receiving Fluanxol Depot. The medication should only be used during pregnancy when the potential benefit to the mother clearly outweighs the potential risk to the foetus.
Newborn babies whose mothers received Fluanxol Depot during the third trimester (final three months) of pregnancy may experience withdrawal symptoms including tremor, muscle stiffness or weakness, sleepiness, agitation, breathing difficulties, and feeding problems. If your baby shows any of these symptoms after birth, contact your doctor promptly.
Small amounts of flupentixol pass into breast milk. If you are breastfeeding, discuss the potential risks with your doctor. The decision to continue breastfeeding or to continue Fluanxol Depot treatment should be made jointly between you and your healthcare provider, taking into account the benefit of breastfeeding for the child and the benefit of therapy for you.
Animal studies have suggested that flupentixol may affect fertility. If you have concerns about fertility, consult your doctor before starting treatment.
Driving and operating machinery
Fluanxol Depot can cause drowsiness, dizziness, and impaired concentration, particularly early in treatment or after dose adjustments. Do not drive or operate machinery until you are confident that your alertness and coordination are not affected. You are personally responsible for assessing whether you are fit to drive or perform tasks requiring concentration. Discuss any concerns with your doctor.
Alcohol
Fluanxol Depot can enhance the sedative effects of alcohol, leading to excessive drowsiness and impaired judgement. You should avoid drinking alcohol while receiving treatment with Fluanxol Depot.
How Does Fluanxol Depot Interact with Other Drugs?
Fluanxol Depot interacts with several medications. Quinidine, codeine, bromocriptine, and cabergoline should not be used concurrently. Drugs that affect heart rhythm (QT-prolonging agents), CNS depressants, and medications metabolised by the same liver enzymes may require dose adjustment. Always inform your doctor of all medications you are taking.
Drug interactions with Fluanxol Depot can occur through pharmacokinetic mechanisms (affecting how the drug is absorbed, distributed, metabolised, or eliminated) and pharmacodynamic mechanisms (additive or opposing effects at the receptor level). It is essential that your doctor and pharmacist know about all medications you take, including prescription drugs, over-the-counter medicines, and herbal supplements.
Contraindicated combinations
The following medications should not be taken at the same time as Fluanxol Depot:
| Drug | Class | Reason |
|---|---|---|
| Quinidine | Antiarrhythmic | Affects heart rhythm; combined use increases risk of serious cardiac arrhythmias |
| Codeine | Opioid analgesic | Enhanced central nervous system depression; reduced analgesic efficacy |
| Bromocriptine | Dopamine agonist | Pharmacological antagonism — opposes the antipsychotic effect |
| Cabergoline | Dopamine agonist | Pharmacological antagonism — opposes the antipsychotic effect |
Major interactions requiring dose adjustment
The following medications may require dose changes when used with Fluanxol Depot:
| Drug / Class | Effect | Action Required |
|---|---|---|
| Tricyclic antidepressants | Mutual increase in plasma levels | Monitor closely; dose adjustment of either drug may be needed |
| Fluoxetine, paroxetine, venlafaxine | May increase flupentixol levels | Monitor for increased side effects; possible dose reduction |
| Antihypertensives | Enhanced blood pressure lowering | Monitor blood pressure; adjust antihypertensive dose if needed |
| Barbiturates | Enhanced sedation; may reduce flupentixol levels | Avoid combination if possible; monitor for reduced efficacy |
| Levodopa (Parkinson's drugs) | Reduced effect of both medications | Generally avoid combination; use alternative if possible |
| QT-prolonging drugs (amiodarone, dofetilide, moxifloxacin, erythromycin, mefloquine, methadone, lithium, cisapride) | Increased risk of QT prolongation and cardiac arrhythmia | ECG monitoring; avoid combination where possible; correct electrolyte imbalances |
| Diuretics | Hypokalaemia increases arrhythmia risk | Monitor potassium levels regularly |
| Other antipsychotics | Additive dopamine blockade; increased side effects | Avoid combining unless specifically recommended by a psychiatrist |
What Is the Correct Dosage of Fluanxol Depot?
Fluanxol Depot is administered as an intramuscular injection into the gluteal muscle. The dose and injection interval are individually determined by your doctor. For the 20 mg/ml formulation, the usual dose is 1–2 ml every 2–4 weeks. For the 100 mg/ml formulation, doses range from 0.5 ml every 4 weeks to 3 ml every 2 weeks. Doses exceeding 2 ml are divided between two injection sites.
The dosage of Fluanxol Depot is highly individualised. Your doctor will determine the optimal dose based on your clinical response, the severity of your condition, your previous experience with antipsychotic medication, and your tolerance of side effects. The goal is to find the lowest effective dose that adequately controls symptoms while minimising adverse effects.
The medication is available in two concentrations, which allows flexible dosing across a wide range:
Adults
20 mg/ml formulation
The usual dose is 20–40 mg (1–2 ml) administered by deep intramuscular injection into the gluteal muscle. The typical injection interval is every 2 to 4 weeks. Your doctor will adjust both the dose and the interval based on your individual response.
100 mg/ml formulation
This higher concentration is used for patients requiring larger doses or who prefer less frequent injections. The usual dose ranges from 50 mg (0.5 ml) every 4 weeks to 300 mg (3 ml) every 2 weeks. Higher concentrations allow the same dose to be administered in a smaller injection volume.
If you require more than 2 ml of medication per injection, the dose will be divided between two separate injection sites (typically one in each gluteal muscle). This reduces discomfort and ensures proper absorption from the injection site.
Switching from oral to depot treatment
If you are switching from oral flupentixol (Fluanxol tablets) to Fluanxol Depot injections, your doctor will typically prescribe both oral tablets and depot injections during a transition period. The oral medication is gradually reduced as the depot formulation reaches therapeutic blood levels. This overlap ensures continuous symptom control during the transition. Full steady-state plasma concentrations from the depot injection may take several injection cycles to achieve.
Elderly patients
Elderly patients are generally more sensitive to the effects and side effects of antipsychotics. The recommended dose for older adults is typically in the lower end of the dosage range. Your doctor will start with a low dose and increase it cautiously, with careful monitoring for orthostatic hypotension (dizziness when standing up), sedation, and movement disorders.
Patients with liver impairment
Caution is required in patients with liver problems, as flupentixol is metabolised by the liver. Your doctor may order additional blood tests to monitor liver function during treatment. Dose reduction may be necessary in patients with significant hepatic impairment.
Children
Fluanxol Depot is not recommended for use in children and adolescents. The safety and efficacy in this age group have not been established.
Missed dose
Because Fluanxol Depot is administered by a healthcare professional on a scheduled basis, missed doses should be uncommon. However, if an injection appointment is missed, contact your doctor or clinic as soon as possible to reschedule. Do not wait until the next planned appointment if a significant delay has occurred, as this may allow psychotic symptoms to recur. Your doctor will advise on the appropriate course of action based on how long the injection is overdue.
Overdose
Because Fluanxol Depot is administered by healthcare professionals, accidental overdose is rare. However, if an overdose occurs, symptoms may include:
- Drowsiness or loss of consciousness
- Abnormal muscle movements or muscle rigidity
- Seizures (convulsions)
- Low blood pressure, weak pulse, rapid heart rate
- Pallor, restlessness
- High or low body temperature
- Changes in heart rhythm, including irregular or slow heartbeat
Overdose with a depot injection requires prolonged medical monitoring because the drug continues to be released from the injection site over weeks. There is no specific antidote. Treatment is supportive and symptomatic, and patients should be monitored in a hospital setting. If you suspect an overdose, contact emergency services immediately.
Treatment duration
It is essential to continue receiving Fluanxol Depot injections regularly, even when you feel well. The underlying psychiatric condition is typically chronic, and stopping treatment prematurely significantly increases the risk of relapse. Your doctor will decide the duration of treatment. Any decision to discontinue should be made gradually and under close medical supervision.
Sudden discontinuation of Fluanxol Depot can cause withdrawal symptoms including nausea, vomiting, loss of appetite, diarrhoea, runny nose, sweating, muscle pain, tingling or prickling sensations, insomnia, restlessness, anxiety, and agitation. Patients may also experience dizziness, alternating feelings of heat and cold, and tremor. Symptoms typically begin 1 to 4 days after the last expected dose and subside within 7 to 14 days. Treatment should always be tapered gradually under medical supervision.
What Are the Side Effects of Fluanxol Depot?
Like all medicines, Fluanxol Depot can cause side effects, although not everyone experiences them. The most common effects include drowsiness, movement disorders (akathisia, tremor, dystonia), and dry mouth. Serious but rare side effects include neuroleptic malignant syndrome, tardive dyskinesia, agranulocytosis, and venous thromboembolism. Most side effects are dose-dependent and may improve over time or with dose adjustment.
Side effects are most pronounced at the beginning of treatment and after dose increases. Many of these effects are related to the dose administered, and your doctor can often reduce their severity by adjusting the dose or the injection interval. It is important to report any new or worsening symptoms to your healthcare provider so that the treatment plan can be optimised for your individual needs.
Serious side effects — seek immediate medical attention
- Unusual movements of the mouth and tongue — this may be an early sign of tardive dyskinesia (uncommon)
- High fever with muscle rigidity, altered consciousness, sweating, and rapid heartbeat — signs of neuroleptic malignant syndrome (very rare, potentially life-threatening)
- Severe allergic reaction with fever, rash, swelling, and sometimes low blood pressure (rare)
- Fever with severely impaired general condition, sore throat, or difficulty urinating — possible signs of agranulocytosis (rare)
- Yellowing of the skin and eyes — possible jaundice (very rare)
- Leg swelling, pain, and redness — possible deep vein thrombosis; chest pain and difficulty breathing may indicate pulmonary embolism (very rare)
Side effects by frequency
Very Common
Affects more than 1 in 10 people
- Drowsiness (somnolence)
- Restlessness — inability to sit or stand still (akathisia)
- Involuntary movements (hyperkinesia)
- Slow or reduced movements (hypokinesia)
- Dry mouth
Common
Affects up to 1 in 10 people
- Rapid heartbeat (tachycardia), palpitations
- Tremor, muscle spasms or abnormal posture (dystonia), dizziness, headache
- Difficulty focusing on near objects, visual disturbances
- Difficulty breathing or painful breathing (dyspnoea)
- Increased saliva production, constipation, vomiting, indigestion, diarrhoea
- Difficulty urinating, urinary retention
- Increased sweating, itching
- Muscle pain (myalgia)
- Increased appetite, weight gain
- Fatigue, weakness (asthenia)
- Insomnia, depression, nervousness, agitation, decreased libido
Uncommon
Affects up to 1 in 100 people
- Jerky movements (dyskinesia), speech difficulties, seizures
- Parkinsonian symptoms (stiffness, shuffling gait, tremor at rest, mask-like face)
- Rotating eye movements (oculogyration)
- Abdominal pain, nausea, flatulence
- Skin rash, light sensitivity (photosensitisation), eczema or dermatitis
- Muscle rigidity
- Decreased appetite, low blood pressure (hypotension), hot flushes
- Redness or tenderness at the injection site
- Abnormal liver function tests
- Sexual dysfunction (delayed ejaculation, erectile problems)
- Confusion
Rare
Affects up to 1 in 1,000 people
- Low platelet count (thrombocytopenia), low white blood cell count (neutropenia, leukopenia)
- Elevated prolactin levels (hyperprolactinaemia)
- High blood sugar (hyperglycaemia), impaired glucose tolerance
- Hypersensitivity reactions
- Breast enlargement in men (gynaecomastia), abnormal milk production (galactorrhoea), absence of menstruation (amenorrhoea)
- Slow heart rate, ECG changes (QT prolongation)
- Irregular heart rhythm (ventricular arrhythmias, ventricular fibrillation, ventricular tachycardia) — rarely life-threatening
- Torsades de pointes (a specific type of irregular heart rhythm)
- Agranulocytosis (severely reduced white blood cells — increases infection risk)
If you experience any side effects, including any not listed above, tell your doctor, pharmacist, or nurse. Reporting suspected side effects after a medicine has been authorised is important, as it helps continuous monitoring of the medicine's benefit-risk balance. You can also report side effects directly to your national medicines regulatory authority.
How Should Fluanxol Depot Be Stored?
Fluanxol Depot should be stored out of the sight and reach of children, kept in the original outer carton to protect from light, and used before the expiry date printed on the packaging. Do not dispose of medicines via wastewater or household waste.
As Fluanxol Depot is administered by healthcare professionals in a clinical setting, you will not normally be responsible for storing the medication yourself. However, the following storage information is provided for completeness:
- Keep out of the sight and reach of children at all times
- Store the ampoules in the original outer carton — the medication is sensitive to light and must be protected from direct light exposure
- Do not use after the expiry date printed on the carton. The expiry date refers to the last day of the stated month
- Do not dispose of medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines that are no longer needed. These measures help protect the environment
What Does Fluanxol Depot Contain?
Fluanxol Depot contains the active substance flupentixol (as decanoate) in a medium-chain triglyceride oil vehicle. It is available as a clear, colourless to slightly yellowish oily solution in glass ampoules at concentrations of 20 mg/ml and 100 mg/ml.
Active substance
The active substance is flupentixol, present in the form of its decanoate ester (flupentixol decanoate). This ester formulation is essential for the slow-release depot mechanism. Each millilitre of Fluanxol Depot contains either 20 mg or 100 mg of flupentixol decanoate, depending on the formulation.
Excipient
The only other ingredient is medium-chain triglycerides (MCT oil), which serves as the oily vehicle in which the active substance is dissolved. This vehicle is essential for the depot mechanism, as it creates a slow-release reservoir at the injection site.
Appearance and packaging
- 20 mg/ml: A clear, colourless to slightly yellowish oil, practically free from particles. Supplied in boxes of 10 glass ampoules, each containing 1 ml
- 100 mg/ml: A clear, yellowish oil, practically free from particles. Supplied in boxes of 10 glass ampoules, each containing 1 ml
Not all pack sizes may be marketed in your country. Fluanxol Depot is manufactured by H. Lundbeck A/S, Ottiliavej 9, 2500 Valby, Denmark.
Frequently Asked Questions About Fluanxol Depot
Fluanxol Depot is a long-acting injectable antipsychotic used to treat schizophrenia and other psychotic disorders. It contains flupentixol decanoate, which is slowly released from the injection site over 2 to 4 weeks. This depot formulation is particularly beneficial for patients who have difficulty maintaining regular oral medication schedules, as it ensures consistent drug levels and reduces the risk of relapse.
Fluanxol Depot is typically administered every 2 to 4 weeks, depending on your individual dose and response. The exact interval is determined by your doctor. Some patients may receive injections every 2 weeks, while others may only need one injection every 4 weeks. Your doctor will monitor your response and adjust the interval accordingly.
If you miss an injection appointment, contact your doctor or clinic as soon as possible. Because Fluanxol Depot provides sustained drug release, a short delay of a few days is unlikely to cause immediate problems. However, longer delays can allow drug levels to fall below the therapeutic range, increasing the risk of symptom recurrence. Do not wait until your next scheduled appointment if significant time has passed — contact your healthcare team promptly.
Yes, weight gain and increased appetite are common side effects of Fluanxol Depot, as with most antipsychotic medications. However, the metabolic effects of first-generation antipsychotics like flupentixol are generally less pronounced than those of some second-generation agents (such as olanzapine or clozapine). Regular weight monitoring, healthy eating, and physical activity are recommended during treatment. Discuss any concerns about weight changes with your doctor.
Fluanxol Depot and oral Fluanxol (tablets) both contain the same active substance, flupentixol, but in different forms. The depot injection uses flupentixol decanoate (an ester form) dissolved in oil, which is released slowly over weeks from the injection site. Oral Fluanxol contains flupentixol dihydrochloride, which is absorbed directly from the gut and requires daily dosing. The depot formulation offers the advantage of consistent drug levels and eliminates the need for daily medication compliance.
Animal studies have shown that flupentixol may affect fertility. Additionally, Fluanxol Depot can raise prolactin levels, which in some cases may lead to menstrual irregularities, breast enlargement, or reduced libido. If you are concerned about fertility or are planning to have children, discuss this with your doctor before starting treatment. Your doctor can monitor prolactin levels and consider alternatives if necessary.
References and Sources
- European Medicines Agency (EMA). Summary of Product Characteristics — Fluanxol Depot (flupentixol decanoate). Last updated 2024.
- National Institute for Health and Care Excellence (NICE). Clinical Guideline CG178: Psychosis and schizophrenia in adults: prevention and management. Updated 2024. Available at: nice.org.uk/guidance/cg178
- Taylor D, Barnes TRE, Young AH. The Maudsley Prescribing Guidelines in Psychiatry. 14th Edition. Wiley-Blackwell; 2024.
- Kishimoto T, Hagi K, Kurokawa S, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry. 2023;84(1):22r14558. doi:10.4088/JCP.22r14558
- World Health Organization (WHO). Model List of Essential Medicines — 23rd List. Geneva: WHO; 2023.
- Joint Formulary Committee. British National Formulary (BNF). Flupentixol decanoate. London: BMJ Group and Pharmaceutical Press; 2024.
- Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951-962. doi:10.1016/S0140-6736(13)60733-3
- Correll CU, Citrome L, Haddad PM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry. 2016;77(suppl 3):1-24.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed physicians and specialists in clinical pharmacology, psychiatry, and pharmaceutical sciences. Our editorial process adheres to international medical standards and evidence-based guidelines.
Content created by physicians with expertise in clinical pharmacology and psychiatric medicine, following the GRADE evidence framework and international prescribing guidelines.
All content independently reviewed by the iMedic Medical Review Board to ensure accuracy, completeness, and adherence to current clinical evidence (EMA, NICE, BNF, WHO guidelines).
This content is free from commercial influence. iMedic receives no pharmaceutical company sponsorship. See our editorial standards for details.
Content is reviewed at least annually and updated when new evidence or guideline changes emerge. Last reviewed: .